Press Releases

OncoDNA, a company specializing in precision medicine for the treatment and diagnosis of cancer, is offering the possibility of using the OncoKDM Lite , a Clinical Decision Support solution, for free for as long as the special containment measures linked to the COVID-19 pandemic are maintained*. This online platform allows the genomic analysis of any patient to be interpreted quickly, easily and without leaving the office. With it, it is also possible to network specialists from aro

Marinomed Biotech AG, a globally active biopharmaceutical company based in Vienna, receives funding from the Austrian Research Promotion Agency (FFG) for the development of a SARS-CoV-2 therapy based on Carragelose®. The aim of the project is to clinically test an inhalation solution with Carragelose® as an acute treatment for viral pneumonia caused by SARS-CoV-2 or other respiratory viruses. "A causal therapy directly in the lungs can shorten the duration of the diseas

Kamada Ltd. and Kedrion Biopharma, two prominent bio-pharmaceutical companies specialized in plasma-derived protein therapeutics, today announced a global collaboration for the development, manufacturing and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for coronavirus patients. The announcement follows separate previous reports by each of the two entities in connection with initiation of development programs

ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX® and SplitCore. METAVAX® is the company´s platform for the development of vaccines built on enveloped virus-like particle nanostructures (eVLPs) based on the duck Hepatitis B small surface antigen. SplitCore is the technology whe

Vivtex Corporation, a pre-clinical biotechnology company focused on the oral delivery of biologics into systemic blood circulation or localized into GI tissue, announced today the publication of a new study that demonstrates a way to expedite the development of new drugs by rapidly testing how well they are absorbed in the small intestine. Vivtex’s GI-ORIS platform could also be used to find new ways to improve the absorption of existing drugs so that they can be taken orally. The artic

EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and the QIMR Berghofer Medical Research Institute (QIMR Berghofer), a non-profit research organization based in Brisbane, Australia, today announced a research collaboration and license agreement to evaluate novel target combinations for their application using EpimAb’s bispecific antibody format, Fabs-In-Tandem Immunoglobulin (FIT-Ig®). Under the terms of the agreemen

NEC Corporation announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines that can drive potent T-cell responses in the majority of the global population. This initiative by the scientific teams within the NEC Group to help combat outbreaks of COVID-19 and support international vaccine development efforts is led by NEC OncoImmunity (NOI) in collaboration with NEC Laboratories Europe (NLE). These AI prediction platforms are based on the

International Pharmaceutical Expo (INTERPHEX), the premier event where industry leaders and professional can experience pharma, bio and device innovation, technology and knowledge from development through commercialization all in one place, and Chemspec USA, dedicated exclusively to the fine and specialty chemicals industry, today announced that the postponed events will take place on July 15-17, 2020 at the Javits Center in New York City. “We know how important INTERPHEX is t

 Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that it has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research (INSERM) spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders. BrainVectis is particularly focused on therapies that restore brain cholesterol metabolism as a treatmen

TOT BIOPHARM International Company Limited is pleased to announce that the randomized Phase III clinical trial of TAB008 (Pusintin) has recently reached the predefined primary endpoint. The Company will continue to push forward the new drug application (NDA) of TAB008 (Pusintin) as scheduled. Ms. Yeh Huang, Chun Ying, General Manager of TOT BIOPHARM, said, "We are very excited about the Phase III Clinical Trial of TAB008 (Pusintin) reaching the predefined primary endpoint. Ther